Pre-Market Earnings Report for July 23, 2025 : T, NEE, GEV, BSX, TMO, APH, CME, FI, MCO, GD, FCX, HLT

On July 23, 2025, a diverse group of companies, including AT&T, NextEra Energy, GE Vernova, Boston Scientific, and Thermo Fisher Scientific, are set to report their Q2 2025 earnings. Analyst consensus forecasts for these companies show a wide range of year-over-year EPS changes, from GE Vernova's substantial projected increase of 125.35% to AT&T's anticipated 10.53% decline. The reports also detail 2025 P/E ratios against industry averages, highlighting companies like GE Vernova, Boston Scientific, Amphenol, and Moody's with implied higher earnings growth potential relative to their peers, while noting others like NextEra Energy and CME Group trading below industry P/E averages. Investors will assess these forward-looking metrics and past earnings consistency to gauge individual company performance and sector trends.

Analysis

The upcoming earnings reports for the quarter ending June 30, 2025, reveal a highly divergent landscape of corporate performance and investor expectations. A clear bifurcation exists between high-growth names and those facing headwinds. Standouts with exceptionally strong growth forecasts include GE Vernova (GEV) and Amphenol (APH), with projected year-over-year EPS increases of 125.35% and 53.49%, respectively. Their significantly elevated P/E ratios (76.68 for GEV, 38.55 for APH) relative to industry peers indicate that the market has already priced in this aggressive growth, creating high bars for performance. However, GEV's prior -25.43% earnings miss in Q4 2024 introduces a material execution risk. In contrast, companies like AT&T (T) and Thermo Fisher Scientific (TMO) are bracing for EPS declines of 10.53% and 2.79%. T's valuation at a P/E of 13.49, below its industry average of 15.70, may reflect these challenges, while TMO's high P/E of 18.13 vs. its industry's 5.30 appears misaligned with its negative growth forecast. A third group, including Boston Scientific (BSX) and Hilton (HLT), shows a pattern of consistent earnings beats coupled with solid double-digit growth forecasts, justifying their premium valuations but also requiring them to continue delivering strong results to maintain investor confidence.

Key Decisions for Investors

• Consider the high-growth potential in names like Amphenol (APH), which has a strong track record of beating estimates, but be wary of the lofty valuation and execution risk associated with GE Vernova (GEV), given its prior significant earnings miss.
• Evaluate consistent performers like Boston Scientific (BSX) and Moody's (MCO) for their reliability, but scrutinize their upcoming guidance to ensure continued growth can support their premium P/E multiples relative to their industries.
• Approach companies with projected earnings declines, such as AT&T (T) and Thermo Fisher (TMO), with caution; T's discounted P/E merits a value-trap analysis, while TMO's high valuation appears vulnerable given its negative growth outlook.
• For valuation-sensitive investors, NextEra Energy (NEE) and Fiserv (FI) may warrant a closer look, as both are projected to grow earnings while trading at P/E ratios below their respective industry averages.